蝶腭神经节刺激治疗慢性丛集性头痛的双盲随机对照试验
该研究在美国21个头痛中心纳入93例慢性丛集性头痛患者,随机分组接受蝶腭神经节刺激或假刺激。结论认为蝶腭神经节刺激可能有效且耐受性良好。
要点
- 开放标签阶段报告9例严重不良事件,其中4例与植入或设备相关。
- 该疗法可能为慢性丛集性头痛提供替代治疗选择,但需进一步研究明确临床定位。
核心结论
- 蝶腭神经节刺激对慢性丛集性头痛似乎有效且耐受性良好,可能提供一种替代治疗方法。
研究设计与样本
- 随机、假刺激对照、平行组、双盲的安全性与有效性研究,在美国21个头痛中心进行。
- 纳入93例22岁及以上慢性丛集性头痛患者,随机1:1分配至蝶腭神经节刺激组(45例)或假刺激对照组(48例)。
- 主要疗效分析纳入刺激组36例和对照组40例至少有一次治疗发作的患者。
主要发现
- 至开放标签阶段结束共报告9例严重不良事件,其中3例与植入操作相关,1例感染归因于设备及植入操作,5例无关。
- 未发生非预期严重不良事件。
临床怎么用
- 对于预防治疗控制不佳的慢性丛集性头痛患者,蝶腭神经节刺激可作为潜在治疗选择。
- 治疗决策需权衡植入操作及设备相关严重不良事件风险。
局限性
- 研究仅在美国21个中心进行,外部推广性需进一步验证。
- 开放标签阶段的安全性数据可能受非盲法影响。
- 作者指出需进一步研究明确该疗法在临床实践中的定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic cluster headache is the most disabling form of cluster headache. The mainstay of treatment is attack prevention, but the available management options have little efficacy and are associated with substantial side-effects. In this study, we aimed to assess the safety and efficacy of sphenopalatine ganglion stimulation for treatment of chronic cluster headache. METHODS: We did a randomised, sham-controlled, parallel group, double-blind, safety and efficacy study at 21 headache centres in the USA. We recruited patients aged 22 years or older with chronic cluster headache, who reported a minimum of four cluster headache attacks per week that were unsuccessfully controlled by preventive treatments. Participants were randomly assigned (1:1) via an online adaptive randomisation procedure to either stimulation of the sphenopalatine ganglion or a sham control that delivered a cutaneous electrical stimulation. Patients and the clinical evaluator and surgeon were masked to group assignment. The primary efficacy endpoint, which was analysed with weighted generalised estimated equation logistic regression models, was the difference between groups in the proportion of stimulation-treated ipsilateral cluster attacks for which relief from pain was achieved 15 min after the start of stimulation without the use of acute drugs before that timepoint. Efficacy analyses were done in all patients who were implanted with a device and provided data for at least one treated attack during the 4-week experimental phase. Safety was assessed in all patients undergoing an implantation procedure up to the end of the open-label phase of the study, which followed the experimental phase. This trial is registered with ClinicalTrials.gov, number NCT02168764. FINDINGS: Between July 9, 2014, and Feb 14, 2017, 93 patients were enrolled and randomly assigned, 45 to the sphenopalatine ganglion stimulation group and 48 to the control group. 36 patients in the sphenopalatine ganglion stimulation group and 40 in the control group had at least one attack during the experimental phase and were included in efficacy analyses. The proportion of attacks for which pain relief was experienced at 15 min was 62·46% (95% CI 49·15-74·12) in the sphenopalatine ganglion stimulation group versus 38·87% (28·60-50·25) in the control group (odds ratio 2·62 [95% CI 1·28-5·34]; p=0·008). Nine serious adverse events were reported by the end of the open-label phase. Three of these serious adverse events were related to the implantation procedure (aspiration during intubation, nausea and vomiting, and venous injury or compromise). A fourth serious adverse event was an infection that was attributed to both the stimulation device and the implantation procedure. The other five serious adverse events were unrelated. There were no unanticipated serious adverse events. INTERPRETATION: Sphenopalatine ganglion stimulation seems efficacious and is well tolerated, and potentially offers an alternative approach to the treatment of chronic cluster headache. Further research is need to clarify its place in clinical practice. FUNDING: Autonomic Technologies.
引用
- Goadsby PJ, Sahai-Srivastava S, Kezirian EJ, et al. Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial. Lancet Neurol. 2019. PMID: 31701891. doi:10.1016/S1474-4422(19)30322-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。